CD8A and non-small cell lung carcinoma: Zhang et al. analyzed six patients with stage I NSCLC undergoing SBRT with a daily dose of 6 Gy or 8 Gy and showed that the proportion of CD8+ T cells among immune cells and the production of proinflammatory cytokines by CD8+ T cells after in vitro stimulation was significantly increased by SBRT [36].